Table 1.

Demographic and Clinical Data for the Study Participants

	Control Subjects	Schizophrenia Patients	P Valuea
N	12	12	N/A
Sex (male)	75%	75%	1
Age (y)	37.4±16.6b	39.6±18.4	.73
Disease duration (y)	N/A	19.0±17.8	N/A
Smoking status (cig/d)	1.7±3.1	2.3±2.4	.55
BPRS scorec	23.1±3.4	38.1±8.4	<.00001
Medicationd	N/A	93.9±130.7	N/A
MoCAe score	25.5±3.0	22.8±3.8	.04

Note: ^aP values from 2-sample t tests between the 2 groups for age, smoking status, Brief Psychiatric Rating Scale (BPRS) and Montreal Cognitive Assessment (MoCA) scores; or from chi-square test for the categorical variable sex.

^bMean ± SD.

^cPlease see Methods section for references. BPRS subscales are reported in supplementary table 1.

^dMedication reported with derived chlorpromazine equivalent dose in dose-year (milligram).

^ePlease see Methods section for references. MoCA subscales are reported in supplementary table 2.